Libya vs South Sudan: Share of the population living with HIV receiving antiretroviral therapy
Libya
50.4%
in 2023
South Sudan
49.7%
in 2024
Libya rank
125th
South Sudan rank
126th
Share of the population living with HIV receiving antiretroviral therapy over time
- Libya
- South Sudan
How they compare
Libya currently reports 50.4% against 49.7% in South Sudan, a difference of 0.7%.
The two have swapped places 1 time across 34 shared years of data; in 1990 it was South Sudan ahead.
Libya ranks 125th and South Sudan ranks 126th of 149 countries.
Libya has averaged higher in every one of the 4 decades both report.
Head to head by decade
| Decade | Libya | South Sudan | Difference | Ahead |
|---|---|---|---|---|
| 1990s | 0.0% | 0.0% | 0.0% | — |
| 2000s | 21.0% | 0.2% | 20.8% | Libya |
| 2010s | 55.4% | 10.4% | 45.0% | Libya |
| 2020s | 49.0% | 36.1% | 13.0% | Libya |
Averages of every year both report within each decade.
Frequently asked questions
- Which has higher share of the population living with hiv receiving antiretroviral therapy, Libya or South Sudan?
- Libya, at 50.4% against 49.7% in South Sudan as of 2023.
- What is the difference in share of the population living with hiv receiving antiretroviral therapy between Libya and South Sudan?
- 0.7%, with Libya ahead.
- How many years of comparable data are there for Libya and South Sudan?
- 34 years are reported by both, from 1990 to 2023.
- How do Libya and South Sudan rank globally for share of the population living with hiv receiving antiretroviral therapy?
- Libya ranks 125th and South Sudan ranks 126th of 149 countries.
- Where does this data come from?
- Joint United Nations Programme on HIV/AIDS (2026) – with minor processing by Our World in Data, published as Share of the population living with HIV receiving antiretroviral therapy. Statizoid refreshes it automatically from the source and publishes the full history for both places.
Individual pages
About this data
Percentage of individuals diagnosed with HIV who are currently receiving antiretroviral therapy. This is the central estimate.